Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 1 - 10 of about 67   

Articles published

GSK 1,476.21 -0.79 (-0.05%)
price chart
Bonds Resurrected as Glaxo Leads Rising Sales
GlaxoSmithKline Plc (GSK)'s $5 billion offering, its first dollar-denominated sale in more than four years, led issuance of at least $55.1 billion this week following $45.8 billion in the period ended April 27, according to data compiled by Bloomberg.
Related articles »  
GSK partner Pronova wins fish oil drug patent fight
LONDON (Reuters) - Norway's Pronova BioPharma PRON.OL, which supplies the omega-3 heart medicine Lovaza to GlaxoSmithKline (GSK.L), has defeated a U.S. patent challenge from two generics companies, sending Pronova shares 28 percent higher ...
GSK partner Pronova wins Lovaza patent case against Teva & Par Pharma  pharmabiz.com
Pronova Defeats Teva, Par In Lovaza Patent Suit  Law360 (subscription)
Related articles »  
Glaxo to Begin Hostile Offer for Human Genome Sciences
Glaxo's bid is part of a wave of takeover activity in the pharmaceutical industry as drugmakers seek new products. Roche Holding AG (ROG) made a hostile offer for Illumina Inc. in January, and abandoned it last month.
GlaxoSmithKline appeals directly to Human Genome Sciences shareholders in ...  Washington Post (blog)
Related articles »  
Glaxo's Melanoma Cocktail Slows Cancer in Study
GlaxoSmithKline Plc (GSK)'s combination of two experimental melanoma medicines slowed the progress of cancer with few skin complications in an early study, suggesting the combo may not have as many side effects as existing single-drug treatments.
Dabrafenib And Trametinib: Melanoma Drug Combo Shows Promise In Small Trial  Huffington Post
Related articles »  
Germany joins UK in spurning GSK's new lupus drug
GSK, Britain's biggest drugmaker, said on Thursday that the judgment from IQWiG was "completely inexplicable from a medical point of view and disregards genuine progress in therapy".
Related articles »  
Glaxo Diabetes Drug Data Revealed Amid Hostile Takeover
GlaxoSmithKline Plc (GSK) will reveal detailed results today on an experimental treatment for diabetes that's part of the reason for a $2.6 billion hostile takeover bid for Human Genome Sciences Inc. (HGSI:US), its partner on the drug.
Related articles »  
GlaxoSmithKline Launches Hostile Takeover Bid for Human Genome Sciences
GlaxoSmithKline Plc (NYSE: GSK), Britain's biggest drugmaker, will mount a $2.6 billion hostile takeover bid for Human Genome Sciences Inc. (NASDAQ: HGSI), the company announced Wednesday.
Related articles »  
Glaxo's Stiefel Unit Loses $1.5 Million Verdict on Buybacks
Stiefel Laboratories lost a $1.5 million jury verdict to a former employee who claimed the company bought back his stock at artificially low prices before its acquisition in 2009 by GlaxoSmithKline Plc. (GSK). Timothy Finnerty won the judgment on May ...
Related articles »  
GSK Says La. Can't Use Outside Attys In $12B Avandia Suit
Law360, New York (May 31, 2012, 4:30 PM ET) -- GlaxoSmithKline PLC urged a Louisiana state court on Thursday to bar the state's attorney general from using private attorneys to pursue a $12 billion Medicaid fraud suit over the safety risks of diabetes ...
GSK addresses Human Genome poison pill
by Laura Board | Published May 23, 2012 at 11:04 AM GlaxoSmithKline plc Wednesday, May 23, tweaked the terms of its hostile $2.59 billion offer for Human Genome Sciences Inc. to address a poison pill mechanism its target put in place last week.
GSK requests board to drop poison pill, blocking takeover of HGS  FinancialNews.co.uk
GlaxoSmithKline won't swallow Human Genome Sciences' poison pill  Washington Business Journal
Related articles »